Angioplasty is a technique that opens clogged arteries using a catheter and a balloon.Stenting occurs following angioplasty, which involves a surgeon inserting a tiny metal device into the artery. The stent keeps the artery open and increases blood flow.
In addition to these therapeutic options, the surgeon may utilize an atherectomy device to remove the plaque.
Peripheral angioplasty and stenting are procedures that unblock a restricted or obstructed artery in extremities, such as arms or legs. This technique has the potential to eliminate the need for more invasive treatments like bypass surgery.
Endovascular intervention is suggested when debilitating claudication persists after effective medical treatment, or when there is significant limb ischemia with ischemic rest discomfort or ischemic tissue loss.
The use of endovascular procedures in the treatment of peripheral artery disease has increased significantly, with femoropopliteal treatments accounting for more than of cases.
The femoropopliteal artery traverses two joint structures (the hip and knee joints) and runs through the thigh’s muscle adductor canal, putting the artery under higher stress from twisting, bending, and longitudinal and radial compression stresses.
Stents in the femoropopliteal system have historically been linked to higher rates of stent fracture, which is linked to higher rates of restenosis and a lower primary patency rate during long-term follow-up.
The Global Peripheral Stent System Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
BIOTRONIK announced that their unique Pulsar-18 T3 peripheral self-expanding stent system has obtained FDA clearance for an enhanced insertion process for endovascular treatments. The business also announced the device’s official commercial debut in the United States, which would begin soon.
The Pulsar-18 T3 stent system is the first to integrate three technologies. When compared to 6-French devices, a 4-French low-profile delivery system may lower the likelihood of access site difficulties and the necessity for closure devices.1.
The tri-axial system with braided shaft design makes it easier to insert the clinically validated Pulsar stent. The Pulsar-18 stent, with its small struts and low chronic outward force (COF)2,3,4, contributes to a lower mean area of restenosis 3,4.
The newly built Pulsar-18 T3 stent system provides clinicians with an easy and ergonomic wheel-operated handle for one-handed stent release boosting the ability to manage deployment.
The Pulsar-18 T3 stent system is intended for treatment in patients with symptomatic de novo, restenotic, or occlusive lesions in the superficial femoral or proximal popliteal arteries, with reference artery diameters ranging from mm and total lesion lengths ranging from
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.